# <u>**Title:**</u> PILocarpine 1.25% Efficacy for management of Uncorrected</u> <u>Presbyopia (PILE-UP Study)</u>

Rohit Saxena<sup>1</sup>, Vinay Gupta<sup>1</sup>, T Velpandian<sup>1</sup>, Tanya Nidhi<sup>1</sup>, Himani Thakur<sup>1</sup>, Jeewan S Titiyal<sup>1</sup>, Namrata Sharma<sup>1</sup>

<sup>1</sup>Dr. R. P. Centre for Ophthalmic Sciences, AIIMS New Delhi

# **Corresponding Author:**

Prof. (Dr.) Namrata Sharma MDProfessor of OphthalmologyDr. R. P. Centre for Ophthalmic SciencesAIIMS New Delhi.Email: namrata.sharma@gmail.com

Short Title: Pilocarpine 1.25% for uncorrected presbyopia

Financial Disclosure: No financial disclosure to make for any author.

Conflict of Interest: No conflict of interest exists for any author.

Keywords: presbyopia, pilocarpine 1.25%, near vision acuity, near correction, pilocarpine.

#### Abstract

**Purpose:** This study aimed to evaluate the efficacy and safety of pilocarpine 1.25% eye drops for improving near vision acuity in presbyopic individuals.

Design: Non-randomized prospective interventional trial

**Methods:** This single-arm prospective interventional trial includes fifty presbyopic individuals aged between 40 to 55, administrated pilocarpine 1.25% eye-drops daily once (9 am, Hour 0) for one month. Visual parameters, including distance corrected near visual acuity (DCNVA), near add power, amplitude of accommodation (AoA), and depth of focus (DoF) along with ocular biometric parameters were assessed at baseline and after one month at hour 3 (12 noon) and hour 6 (3 p.m.). Adverse effects were monitored.

**Results:** After one month of pilocarpine treatment, a significant improvement was observed in DCNVA ( $0.64\pm0.2$  to  $0.26\pm0.11$ , P:<0.001) along with a decrease in near add power ( $1.43\pm0.43$  D to  $0.42\pm0.22$  D, P:<0.001). The AoA increased ( $3.23\pm0.74$ D to  $3.92\pm0.93$ D, P:0.005), and DoF widened ( $0.72\pm0.18$ D to  $0.81\pm0.26$ D, P:0.038). No change in ocular biometry parameters was observed. The change in DCNVA showed strong positive correlations with change in near add (r: 0.84, P:<0.001) and AoA (r: 0.66, P:0.04). Adverse effects were mild and did not lead to discontinuation.

**Conclusion:** Pilocarpine 1.25% eye drops demonstrated statistically significant improvements in DCNVA, near add, AoA, and DoF after one month of treatment. Pilocarpine 1.25% eye drops shown increase in the amplitude of accommodation and depth of focus; without any significant change in ocular biometry parameters. The use of pilocarpine 1.25% eye drops can be an alternative intervention for enhancing near vision acuity of presbyopic subjects.

### 1 Introduction

Presbyopia is an age-related condition resulting in loss of the eye's ability to focus on near objects due to progressive loss of accommodation with increasing age. Accommodation loss is likely because of loss of contraction power in ciliary body and viscoelasticity of the crystalline lens resulting in hardening of lens.<sup>1</sup> Uncorrected presbyopia globally affect 1.8 billion people approximately, 826 million of whom had near vision impairment because of no, or inadequate, vision correction.<sup>2</sup> It decrease the quality of life by affecting individual's emotional well being and ability to do daily activities.<sup>3</sup>

9 The current options for correction of presbyopia include spectacle for near work e.g. single 10 vision reading glasses, bifocal, multifocal progressive glasses; multifocal contact lens and 11 some surgical techniques.<sup>4-6</sup> But none of these methods able to restore dynamic range of 12 accommodation.<sup>7</sup> Multifocal glasses are often considers to be inconvenient by many and 13 require need to direct the visual axes in a particular direction for adequate near vision.<sup>8</sup>

Pharmacological treatment for presbyopia has been under investigation recently.<sup>9-12</sup> 14 15 Pilocarpine is a cholinergic muscarinic receptor agonist, and may expand the diversity of 16 existing strategies for treating presbyopia. It acts by enhancing depth of focus as well as accommodation for the treatment of presbyopia.<sup>7,10</sup> Pilocarpine contracts ciliary muscles and 17 iris sphincter muscles by binding to and activating muscarinic M3 receptors.<sup>13</sup> Pupillary 18 constriction caused by contraction of the iris sphincter create a pinhole effect that improves 19 the ability to focus on near objects by increasing depth of focus.<sup>14</sup> Also, accommodation is 20 enhanced by contraction of ciliary muscles which also improve the near vision. 21

22 Pilocarpine 1.25% has been shown as a potential alternative for presbyopia treatment in recent studies,<sup>10-12,15</sup> and has been approved by FDA<sup>16</sup> as treatment of presbyopia. However 23 current available studies are mainly in Caucasian population, its effect on the eyes with 24 25 pigmented iris has not been evaluated. Pilocarpine demonstrates greater bioavailability in 26 pigmented eyes, suggesting a biophase preference. Subjects with blue and brown eyes 27 exhibited comparable levels of miosis when administered pilocarpine, yet the onset of peak effects was notably prolonged in the latter group.<sup>17</sup> Furthermore, there exists a positive 28 correlation between the density of pigmentation and the uptake capacity of pilocarpine.<sup>18</sup> 29 30 Major unaddressed questions related to pilocarpine for management of presbyopia are safety, 31 optimum duration, and effect on ocular biometry parameters. There is lack of information on

the efficacy and safety of pilocarpine 1.25% for treatment of presbyopia among pigmentedeyes.

This study aims to evaluate the effect of pilocarpine 1.25% eye drops on near vision acuity and accommodation (efficacy outcomes); and associated side effect (if any) of pilocarpine 1.25% eye drops as measure by pupil size, ocular biometry, and occurrence of adverse events (safety outcomes).

#### 38 Methodology

The study was a prospective interventional trial [CTRI: REF/2022/07/056632] following the principles outlined in the Declaration of Helsinki. The study protocol received approval from the Institute Ethics Committee [Ref. No.: IEC-623/15.07.2022], and all participants provided written informed consent.

43 The inclusion criteria encompassed individuals aged 40 to 55 years, in good general health, 44 and exhibiting both objective and subjective evidence of presbyopia. A thorough assessment 45 of ocular and general health was conducted, including vision evaluation, slit-lamp 46 examination for anterior segment health, cycloplegic refraction using tropicamide 1%, fundus 47 examination and measurement of intraocular pressure. Emmetropes were defined as individuals with a spherical equivalent refractive error between -0.50 D and +0.50 D for 48 49 distance in each eye, along with < 0.75 D of astigmatism. Key inclusion criteria required 50 participants to have high contrast uncorrected logMAR distance visual acuity better than or 51 equal to 0.1, best corrected near visual acuity of N6 at 33cm in both eyes, intraocular pressure 52 (IOP) between 10 to 21 mm of Hg, mesopic pupil size < 8.00 mm, and photopic pupil size >53 3.00 mm. On the other hand, key exclusion criteria involved the presence of severe dry eye 54 disease, corneal abnormalities, cataract, or any other retinal/ocular pathology, a history of 55 ocular surgery and/or phakic intraocular lens implantation, migraine headaches, angle-closure 56 glaucoma, abnormal pupil shape, anisocoria >1 mm, amblyopia, and known allergy to 57 pilocarpine eye drops.

Throughout the study, participants received pilocarpine 1.25% eye drops once daily at 9 am in both eyes for one month, prepared by our in-house pharmacy compliant with good laboratory practice. Isotonic pilocarpine 1.25% eye drops (1.25% of pilocarpine nitrate preserved with chlorbutol) were compounded from sterile dispensing facility of our pharmacy. Study visits were scheduled at baseline and a one-month follow-up. The data was recorded at 12 noon (Hour 3) and 3 pm (Hour 6). During the visits, objective and subjective

64 refraction, along with near add, were performed. The patients' acceptance of distance and 65 near vision was recorded. Parameters noted included spherical equivalent refractive error, 66 near correction, uncorrected visual acuity for both distance and near, best corrected visual 67 acuity for both distance and near, and distance corrected near visual acuity. The near visual 68 acuity was measured using near logMAR chart [ETDRS 2000 series (logarithmic chart 69 calibrated for 33 cm), Precision Vision, Woodstock, IL, USA] at 33 cm in mesopic light 70 conditions (10 lux at target). Additionally, optical biometry using partial interferometry optical biometer (IOL Master® 700, Zeiss, Germany) was conducted to measure axial length 71 72 (AL), keratometry (Km), anterior chamber depth (ACD), vitreous chamber depth (VCD), and 73 lens thickness (LT). The near point of accommodation was calculated using the RAF ruler, 74 and the amplitude of accommodation (AoA) was determined as the inverse of this value. 75 Pupil size was measured using automated, hand held, infrared pupillometer (NeurOptics 76 PLR □ 200, Irvine, USA); and I-tracey (Tracey<sup>TM</sup> Technologies, Houston, TX) was employed 77 to document depth of focus (DoF). Three readings were taken and median was recorded for 78 purpose of analysis. The participants were asked to report any adverse effect such as 79 headache, flashes of light etc. The individual was inquired about their response to the 80 treatment, specifically regarding any challenges they experienced in performing routine near 81 tasks and during close work or delicate tasks. This included questions about whether they 82 encountered minimal or no difficulties in performing these tasks, as well as whether they 83 were unable to carry out routine or delicate tasks even with the use of pilocarpine 1.25%. An 84 anterior segment examination using slit lamp and central as well as peripheral retinal 85 examination using indirect ophthalmoscopy was done at 1 month follow up.

After conducting a pilot study at the study centre from September 2022 to October 2022, we performed a conservative estimation of the effect size. To detect a minimum difference of 5 lines (0.5 logMAR visual acuity) on the logMAR near visual acuity chart, with a significance level of 0.05 and a power of 90%, sample size of 43 subjects is required. Accounting for an attrition rate of 15%, we determined that a total sample size of 50 subjects would be necessary.

92 Statistical analysis was conducted using IBM SPSS Statistics software, Version 25.0 (IBM 93 Corp., Armonk, NY). The variables were represented in terms of mean and standard 94 deviation. For a comprehensive examination of the data, linear mixed effects models were 95 employed to address missing data at random and account for the correlation between the two 96 eyes within each participant. Clustered data from both eyes of the same patient were

97 combined using robust standard error.<sup>19</sup> To assess the clinical significance of changes in
98 variable characteristics, the P value was calculated using paired sample t-test for intra-group
99 comparisons. P value of less than 0.05 was considered statistically significant.

#### 100 **Results**

The study enrolled 50 subjects with a mean age of  $45.3 \pm 5.1$  years, of whom 45% were males. All the subjects had dark brown iris. There were no statistically significant differences observed in the baseline characteristics between the measurements taken at 12 pm and 3 pm at baseline (*P* > 0.05 for all parameters). (*Table 1*)

105 The mean follow-up time was  $29.8 \pm 1.6$  days. At the one-month follow-up (12 noon), there 106 was a statistically significant improvement in the logMAR distance corrected near visual 107 acuity (DCNVA), which changed from  $0.74 \pm 0.2$  at baseline to  $0.36 \pm 0.11$  at one month (P 108 < 0.001). This improvement was accompanied by a decrease in the near add power, from 109  $1.43 \pm 0.43$  D at baseline to  $0.42 \pm 0.22$  D at one month (P < 0.001). Additionally, an 110 increase in the Amplitude of Accommodation was observed, changing from  $3.23 \pm 0.74$  D to 111  $3.92 \pm 0.93$  D (P = 0.005), along with an increase in the Depth of Focus from 0.72 ± 0.18 D to  $0.81 \pm 0.26$  D (P = 0.038). No significant change observed in any other studied 112 113 parameters. (Table 2)

Furthermore, there was a strong positive correlation between the change in DCNVA & the change in Near Add (r: 0.84, P < 0.001); and change in DCNVA & change in amplitude of accommodation (AoA) (r: 0.66, P: 0.04). No strong corelation observed between change in DCNVA & change in depth of focus (r: 0.32. P: 0.075); and change in near add & change in depth of focus (r: 0.28, P: 0.062). However, a strong corelation found between change in AoA & change in near add (r: 0.61, P: 0.048); and change in AoA & change in depth of focus (r: 0.71, P: 0.036).

121 At 1 month follow-up, significant difference was observed in DCNVA (*P*: .046), amount of

near add (*P*: .031), and amplitude of accommodation (*P*: .048), between hour 3 (12 noon) and

hour 6 (3 pm) post instillation of pilocarpine 1.25% drop. (Table 3) However all these 3

- 124 parameters remained significantly better at 1 month compared to the baseline values at 6 hour
- 125 (3 pm) (P < 0.001). (Table 4)
- 126 The patient satisfaction response to treatment summarized in *Table 5*.
- 127 The adverse effects reported by patient includes headache (8/50, 16%), eye pain (1/50, 2%),
- 128 visual blur (2/50, 4%) and irritation (2/50, 4%). Symptoms are during initial days of

treatment and was not severe. No patient discontinued using pilocarpine 1.25% due to adverse effect. No relevant anterior segment as well as retinal changes was observed at 1 month follow up when accessed through slit-lamp examination and dilated fundus examination respectively.

133

## 134 Discussion

135

In this prospective interventional study, we assessed the impact of 1.25% pilocarpine eye 136 137 drops on both near vision acuity and accommodation, while also monitoring any potential adverse events associated with the drug. After one month, an improvement in Distance 138 139 Corrected Near Visual Acuity (DCNVA) at hour 3, along with a simultaneous reduction in 140 the Near-Add required by the patient was observed. The term "near add" refers to the additional optical power needed to achieve clear near vision, typically in the form of reading 141 glasses or bifocal/multifocal lenses. By contracting the ciliary muscle, pilocarpine increases 142 the eye's ability to adjust its focus for near vision tasks,<sup>18</sup> reducing the need for additional 143 144 optical correction (near add) to achieve clear near vision.

145 Our study showed a significant improvement in DCNVA, AoA, DoF along with reduction in 146 near add requirement after 1 month of treatment as compared to baseline. GEMINI-1 Phase 3 Randomized Controlled Trial (RCT)<sup>12</sup>, pilocarpine 1.25% demonstrated superiority over the 147 148 vehicle in terms of DCNVA on day 30, hours 3, and 6. Specifically, on day 30, hour 3, 30.7% of participants in the pilocarpine 1.25% group showed an improvement of 3 or more lines in 149 150 DCNVA, compared to only 8.1% in the vehicle group. At hour 6, these percentages were 151 18.4% and 8.8%. In our study 44% of participant at hour 3 and 30% of participant at hour 6 152 showed an improvement of 0.5 logMAR (5 lines on logMAR scale). Our study revealed a 153 significant decrease in logMAR DCNVA at hour 6 compared to hour 3 on day 30. This 154 suggests that the effect of pilocarpine on near vision acuity may start to diminish over time 155 after the initial application, and the efficacy for near addition tends to be higher during the 156 first few hours following application; though the effect of pilocarpine 1.25% was retained at 157 hour 6 when compared to baseline The VIRGO trial had demonstrated significant benefit with Pilocarpine 1.25% twice daily compared to placebo.<sup>15</sup> It is possible that twice daily dose 158 159 may provide more sustained effect.

There was no change observed after 1 month of using pilocarpine 1.25% in Best-CorrectedVisual Acuity (BCVA) for distance. This finding aligns with the GEMINI-1 Phase 3 RCT,

where no participants with a DCNVA improvement of 3 lines or more experienced a loss of more than 5 letters in BCVA for distance on day 30.<sup>12</sup>

164 In addition to evaluating near vision acuity, our study also compared the amplitude of 165 accommodation and depth of focus at baseline and after 1 month of treatment. We observed a 166 significant increase in the amplitude of accommodation and depth of focus at day 30, hour 3. 167 The increase in the amplitude of accommodation after 1 month of using pilocarpine 1.25% is 168 likely due to the drug's pharmacological effects on the eye's anatomy and physiology. These 169 findings indicate that pilocarpine's mechanism of action involves pupillary constriction, 170 which leads to an increase in depth of focus, as well as contraction of the ciliary muscle, 171 resulting in an increased amplitude of accommodation. When the ciliary muscle contracts, it 172 causes the lens of the eye to change its shape, becoming more rounded. This increased 173 curvature of the lens enhances its refractive power, enabling the eye to focus on nearby 174 objects. Also, a greater depth of focus, such as that achieved through the use of pilocarpine 175 eye drops, can enhance near vision by expanding the range of distances at which near objects 176 can be seen clearly without straining the eyes or constantly adjusting the focus.

The strong correlation observed between the change in near add and the amplitude of accommodation suggests that the improvement in near vision acuity is directly related to the increased ability of the eye to accommodate for near objects. As pilocarpine induces pupillary constriction and ciliary muscle contraction, it enhances the eye's accommodative response, resulting in improved near vision and a decreased reliance on additional optical correction (near add) for near tasks.

183 Despite independent improvements in both near visual acuity and depth of focus, the study 184 did not find a statistical correlation between the two. In other words, the improvement in near 185 visual acuity did not necessarily correlate with the increase in depth of focus. While pilocarpine eye drops can lead to improvements in near visual acuity and depth of focus 186 independently, other factors or mechanisms may be responsible for these effects,<sup>7,20</sup> and they 187 188 might not be directly related to each other. The study's findings provide valuable insights into 189 the effects of pilocarpine on various visual parameters, but further research may be needed to 190 fully understand the underlying mechanisms and potential interactions between near visual 191 acuity and depth of focus in response to pilocarpine treatment.

Notably, the daily use of 1.25% pilocarpine was generally well-tolerated, with minimal side effects. Ninety percent of participants in our study indicated experiencing either no difficulties or only minimal challenges when engaging in both routine near work and at closedistances/more-intricate tasks with using pilocarpine 1.25%. In this study, despite the

196 pupillary constriction induced by pilocarpine, there was no significant change in the size of 197 the pupil measured in both dim and well-lit conditions at the end of the 1-month treatment 198 period. This finding suggests that the effect of pilocarpine on pupil size was likely not 199 sustained over the long term or was not significant enough to produce a measurable change in 200 pupil size in the studied population. The lack of significant change in pupil size after 1 month 201 of pilocarpine use may be considered beneficial, as excessive or prolonged pupillary 202 constriction could potentially lead to visual disturbances and discomfort, especially in low-203 light conditions. While earlier research had documented instances of retinal detachment associated with the use of pilocarpine 1.25% for presbyopia,<sup>21-22</sup> our study did not identify 204 any occurrences of retinal detachment or other retinal pathologies. However, individual 205 206 responses to medications should always be monitored by healthcare professionals to ensure 207 safety and optimal treatment outcomes.

208 This study has certain limitations. Firstly, being a non-randomized trial, there is a potential 209 for biases when compared to blinded randomized controlled trials. Secondly, the sample size 210 is modest; a larger cohort studied over an extended period would offer deeper insights into 211 the drug's efficacy and safety. However, this study stands out as the pioneering research 212 documenting the efficacy of pilocarpine in eyes with pigmented iris, setting a foundation for 213 future studies. A key strength of our study is the quantification of ocular biometry 214 parameters, amplitude of accommodation and depth of focus among participants administered 215 with pilocarpine 1.25% for presbyopia. To our current understanding, this is the first study 216 quantifying accommodation and depth of focus and correlating them with the adjustments in 217 near add required and enhancements in near visual acuity; among individuals given 218 pilocarpine 1.25% for presbyopia.

219

220 In conclusion, the study's findings suggest that the use of pilocarpine 1.25% eye drops can be 221 an alternative intervention for enhancing near vision acuity in the presbyopic subjects. 222 Pilocarpine 1.25% eye drops shows statistically significant improvement in uncorrected near 223 visual acuity; increase in the amplitude of accommodation and depth of focus among studied 224 presbyopic individuals, without any significant change in ocular biometry parameters. No 225 occurrence of retinal detachment or any other severe adverse effect was observed in our 226 study. However further research and individual assessments would be necessary to fully 227 understand and optimize the benefits of pilocarpine for near vision improvement in different 228 clinical contexts.

229					
230	All au	thors have completed and submitted the ICMJE form for disclosure of potential			
231					
232	make f	for any author(s).			
233	-				
234	Refer	ence			
235	5				
236	1	Radhakrishnan H, Charman WN. Age-related changes in static accommodation and			
237	1.	accommodative missis. <i>Ophthalmic Physiol Opt.</i> 2007;27(4):342-52.			
238	2	Fricke TR, Tanhan N, Resnikoff S <i>et al.</i> Global prevalence of presbyopia and vision			
239	2.	impairment from uncorrected presbyopia: systematic review, meta-analysis and			
240		modelling. <i>Ophthalmology</i> . 2018;125:1492-9.			
241	3	McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia			
242	5.	with vision-targeted health-related quality of life. Arch Ophthalmol.			
243		2003;121(11):1577-81.			
244	4	Charman WN. Developments in the correction of presbyopia I: spectacle and contact			
245	т.	lenses. Ophthalmic Physiol Opt. 2014;34:8-29.			
246	5	Balgos MJTD, Vargas V, Alió JL. Correction of presbyopia: an integrated update for			
247	5.	the practical surgeon. <i>Taiwan J Ophthalmol.</i> 2018;8:121-40.			
248	6	Seyaddain O, Hohensinn M, Riha W <i>et al.</i> Small aperture corneal inlay for the			
249	0.	correction of presbyopia: 3 year follow up. J Cataract Refract Surg. 2012;38:35-45.			
250	7	Wolffsohn JS, Davies LN. Presbyopia: effectiveness of correction strategies. <i>Prog</i>			
251	/.	Retin Eye Res. 2019;68:124-43.			
252	8	Lord SR, Dayhew J, Sc BA, Howland A. Multifocal glasses impair edge-contrast			
252	0.	sensitivity and depth perception and increase the risk of falls in older people. J Am			
254		Geriatr Soc. 2002;50:1760-6.			
255	9	Grzybowski A, Markeviciute A, Zemaitiene R. A Review of Pharmacological			
256		Presbyopia Treatment. Asia Pac J Ophthalmol (Phila). 2020;9(3):226-33.			
257	10	Price Jr FW, Hom M, Moshirfar M <i>et al.</i> Combinations of Pilocarpine and			
258		Oxymetazoline for the Pharmacological Treatment of Presbyopia: Two Randomized			
259		Phase 2 Studies. <i>Ophthalmol Sci</i> . 2021;1(4):100065.			
260	11.	Betinaa O, Giovannaa B. Pharmacological strategies for treating presbyopia. <i>Current</i>			
261		<i>Opinion Ophthalmol.</i> 2021;32(4):319-23.			
262	12	Waring GO, Price FW, Wirta D et al. Safety and Efficacy of AGN-190584 in			
263		Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.			
264		JAMA Ophthalmol. 2022;140(4):363-71.			
265	13	Drummond PD. The effect of light intensity and dose of dilute pilocarpine eyedrops			
266		on pupillary constriction in healthy subjects. Am J Ophthalmol. 1991;112:195-9.			
267	14	. Kim WS, Park IK, Chun YS. Quantitative analysis of functional changes caused by			
268		pinhole glasses. Invest Ophthalmol Vis Sci. 2014;55:6679-85.			
269	15	Kannarr S, El-Harazi SM, Moshirfar M et al. Safety and Efficacy of Twice-Daily			
270		Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked,			
271		Controlled Study. <i>Am J Ophthalmol.</i> 2023;253:189-200.			
272	16	. Meghpara BB, Lee JK, Rapuano CJ, Mian SI, Ho AC. Pilocarpine 1.25% and the			
273	- 01	changing landscape of presbyopia treatment. <i>Curr Opin Ophthalmol.</i> 2022;33(4):269-			
274		74.			

275	17. Salminen L, Urtti A. Effect of Ocular Pigmentation on Ocular Disposition,
276	Metabolism and Biophasic Availability of Pilocarpine. In: Greve, E.L., Leydhecker,
277	W., Raitta, C. (eds) Second European Glaucoma Symposium, Helsinki, May 1984.
278	Springer, Dordrecht. Documenta Ophthalmologica Proceedings Series. 1985;43:91-2.
279	https://doi.org/10.1007/978-94-009-5516-5 17.

- 18. Lyons JS, Krohn DL. Pilocarpine uptake by pigmented uveal tissue. Am J
   Ophthalmol. 1973;75(5):885-8.
- 19. Fan Q, Teo YY, Saw SM. Application of Advanced Statistics in Ophthalmology.
   *Invest Ophthalmol Vis Sci.* 2011;52:6059-65.
- 284 20. Wendt M, Glasser A. Topical and intravenous pilocarpine stimulated accommodation
   285 in anesthetized rhesus monkeys. *Exp Eye Res.* 2010;90(5):605-16.
- 286 21. Amarikwa L, Michalak SM, Caul S, Mruthyunjaya P, Rahimy E. Vitreofoveal
   287 Traction Associated With Pilocarpine for Presbyopia. *Ophthalmic Surg Lasers* 288 *Imaging Retina*. 2022;53(7):410-1.
- 289 22. Al-Khersan H, Flynn HW Jr, Townsend JH. Retinal Detachments Associated With
   290 Topical Pilocarpine Use for Presbyopia. *Am J Ophthalmol.* 2022;242:52-5.
- 291
- 292
- 293

#### 294 Table 1: Mean value of baseline parameters of study subjects

<b>Baseline Study Parameters</b>	12 noon	3 pm
UCVA (logMAR)	$0.04 \pm 0.02$	$0.04 \pm 0.02$
BCVA (logMAR)	$0.00 \pm 0.00$	$0.00\pm0.00$
DCNVA (logMAR)	$0.74 \pm 0.2$	$0.76 \pm 0.22$
BCNVA spectacles (logMAR)	$0.12 \pm 0.01$	$0.12\pm0.01$
SE Ref. error (distance) (D)	$0.08 \pm 0.41$	$0.1 \pm 0.32$
Near Addition (D)	$1.43 \pm 0.43$	$1.46\pm0.42$
IOP (mm of Hg)	$16.2 \pm 2.5$	$15.9 \pm 2.7$
Pupil size Mesopic (mm)	$5.3 \pm 1.1$	$5.5 \pm 1.3$
Pupil size photopic (mm)	$3.7\pm0.6$	$3.8 \pm 0.6$
Amplitude of accommodation (D)	$3.23 \pm 0.74$	$3.14\pm0.62$
Depth of focus (D)	$0.72 \pm 0.18$	$0.68 \pm 0.2$
Axial length (mm)	$23.59 \pm 2.22$	$23.6\pm2.1$
Mean Km (D)	$43.78 \pm 3.7$	$43.85 \pm 3.4$
ACD (mm)	$3.25 \pm 0.33$	$3.26\pm0.31$
LT (mm)	$3.41 \pm 0.64$	$3.42 \pm 0.7$

295 UCVA: Uncorrected distance visual acuity; BCVA: best corrected distance visual acuity; DCNVA: distance

296 corrected near visual acuity; SE: Spherical equivalent; IOP: Intraocular pressure; ACD: Anterior chamber depth;

297 LT: lens thickness.

298

299 Table 2: Mean characteristics of study subject at baseline and 1 month follow-up

Study parameters	Baseline (12 noon)	1 month (12 noon)	P value
UCVA (logMAR)	$0.04\pm0.02$	$0.06\pm0.02$	0.15
BCVA (logMAR)	$0.00 \pm 0.00$	$0.00 \pm 0.00$	1
DCNVA (logMAR)	$0.74 \pm 0.2$	$0.36 \pm 0.11$	<0.001
BCNVA spectacles (logMAR)	$0.12 \pm 0.01$	$0.11 \pm 0.02$	0.25
SE Ref. error (distance) (D)	$0.08\pm0.41$	$0.13 \pm 0.39$	0.12

Near Addition (D)	$1.43 \pm 0.43$	$0.42 \pm 0.22$	<0.001
IOP (mm of Hg)	$16.2 \pm 2.5$	$16.8 \pm 3.5$	0.2
Pupil size Mesopic (mm)	$5.3 \pm 1.1$	$5.13 \pm 1.4$	0.066
Pupil size photopic (mm)	$3.7 \pm 0.6$	$3.51 \pm 0.5$	0.052
Amplitude of accommodation	$3.23 \pm 0.74$	$3.92 \pm 0.93$	0.005
(D)			
Depth of focus (D)	$0.72 \pm 0.18$	$0.81 \pm 0.26$	0.038
Axial length (mm)	$23.59 \pm 2.22$	$23.62 \pm 2.24$	0.11
Mean Km (D)	$43.78 \pm 3.7$	$43.89 \pm 4.1$	0.14
ACD (mm)	$3.25 \pm 0.33$	$3.27 \pm 0.39$	0.08
LT (mm)	$3.41 \pm 0.64$	$3.43\pm0.81$	0.071

300 UCVA: Uncorrected distance visual acuity; BCVA: best corrected distance visual acuity; DCNVA: distance

301 corrected near visual acuity; SE: Spherical equivalent; IOP: Intraocular pressure; ACD: Anterior chamber depth;

302 LT: lens thickness.

303

Table 3: Mean characteristics of study subjects at hour 3 and hour 6

1 month follow-up	12 noon (Hour 3)	3 pm (Hour 6)	P value
UCVA (logMAR)	$0.06\pm0.02$	$0.04 \pm 0.04$	0.25
BCVA (logMAR)	$0.00\pm0.00$	$0.00 \pm 0.00$	1
DCNVA (logMAR)	$0.36\pm0.11$	$0.44 \pm 0.14$	0.046
BCNVA spectacles (logMAR)	$0.11\pm0.02$	$0.12 \pm 0.02$	0.17
SE Ref. error (distance) (D)	$0.13\pm0.39$	$0.08 \pm 0.4$	0.08
Near Addition (D)	$0.42 \pm 0.22$	$0.52 \pm 0.26$	0.031
IOP (mm of Hg)	$16.8 \pm 3.5$	$16.6 \pm 4.1$	0.22
Pupil size Mesopic (mm)	$5.13 \pm 1.4$	$5.39 \pm 1.1$	0.073
Pupil size photopic (mm)	$3.51 \pm 0.5$	$3.72 \pm 0.8$	0.01
Amplitude of accommodation (D)	$3.92 \pm 0.93$	$3.64 \pm 0.62$	0.048
Depth of focus (D)	$0.81 \pm 0.26$	$0.76 \pm 0.21$	0.1
Axial length (mm)	$23.62 \pm 2.24$	$23.61 \pm 2.7$	0.36
Mean Km (D)	$43.89 \pm 4.1$	$43.75 \pm 3.9$	0.14
ACD (mm)	$3.27 \pm 0.39$	$3.25 \pm 0.44$	0.13
LT (mm)	$3.43\pm0.81$	$3.43\pm0.74$	0.16

305 UCVA: Uncorrected distance visual acuity; BCVA: best corrected distance visual acuity; DCNVA: distance

corrected near visual acuity; SE: Spherical equivalent; IOP: Intraocular pressure; ACD: Anterior chamber depth;
 LT: lens thickness.

308

Table 4: Mean characteristics of study subjects at baseline (3pm) versus 1 month follow-up

310 <u>(3pm)</u>

1 month follow-up	Baseline (3 pm)	1 month follow-up	P value
		3 pm (Hour 6)	
UCVA (logMAR)	$0.04 \pm 0.02$	$0.04 \pm 0.04$	0.72
BCVA (logMAR)	$0.00 \pm 0.00$	$0.00 \pm 0.00$	1
DCNVA (logMAR)	$0.76\pm0.22$	$0.44 \pm 0.14$	>0.001
BCNVA spectacles (logMAR)	$0.12 \pm 0.01$	$0.12 \pm 0.02$	0.54
SE Ref. error (distance) (D)	$0.1 \pm 0.32$	$0.08 \pm 0.4$	0.17
Near Addition (D)	$1.46\pm0.42$	$0.52 \pm 0.26$	>0.001
IOP (mm of Hg)	$15.9 \pm 2.7$	$16.6 \pm 4.1$	0.15
Pupil size Mesopic (mm)	$5.5 \pm 1.3$	$5.39 \pm 1.1$	0. 055
Pupil size photopic (mm)	$3.8\pm0.6$	$3.72 \pm 0.8$	0.062
Amplitude of accommodation (D)	$3.14\pm0.62$	$3.64\pm0.62$	>0.001

Depth of focus (D)	$0.68 \pm 0.2$	$0.76\pm0.21$	0.048
Axial length (mm)	$23.6 \pm 2.1$	$23.61 \pm 2.7$	0.48
Mean Km (D)	$43.85 \pm 3.4$	$43.75 \pm 3.9$	0.2
ACD (mm)	$3.26 \pm 0.31$	$3.25 \pm 0.44$	0.31
LT (mm)	$3.42 \pm 0.7$	$3.43\pm0.74$	0.12

311 UCVA: Uncorrected distance visual acuity; BCVA: best corrected distance visual acuity; DCNVA: distance

corrected near visual acuity; SE: Spherical equivalent; IOP: Intraocular pressure; ACD: Anterior chamber depth;
 LT: lens thickness.

314

315

## 316 Table 5: Patient satisfaction response to treatment

Response	Number
No difficulty in doing routine near work as well as fine work	30/50 (60%)
Easily doing routine near work, but slight difficulty in doing fine work	15/50 (30%)
Slight difficulty in doing routine near work, can't do fine work	4/50 (8%)
Can't do routine near work properly	1/50 (2%)

317

318